A Multicenter, Retrospective Study Assessing the Long-Term Efficacy and Safety of Everolimus in Patients with Low (G1) and Intermediate Grade (G2) Advanced, Nonfunctioning, Pancreatic Neuroendocrine Tumors (pNETs)
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2017 New trial record